GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adynxx Inc (OTCPK:ADYX) » Definitions » Cyclically Adjusted PB Ratio

Adynxx (Adynxx) Cyclically Adjusted PB Ratio : (As of May. 15, 2024)


View and export this data going back to 1998. Start your Free Trial

What is Adynxx Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Adynxx Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Adynxx's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Adynxx Cyclically Adjusted PB Ratio Chart

Adynxx Annual Data
Trend Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Adynxx Quarterly Data
Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Adynxx's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Adynxx's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Adynxx's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Adynxx's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Adynxx's Cyclically Adjusted PB Ratio falls into.



Adynxx Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Adynxx's Cyclically Adjusted Book per Share for the quarter that ended in Sep. 2019 is calculated as:

For example, Adynxx's adjusted Book Value per Share data for the three months ended in Sep. 2019 was:

Adj_Book=Book Value per Share/CPI of Sep. 2019 (Change)*Current CPI (Sep. 2019)
=-1.905/108.3294*108.3294
=-1.905

Current CPI (Sep. 2019) = 108.3294.

Adynxx Quarterly Data

Book Value per Share CPI Adj_Book
200912 168.934 91.111 200.859
201003 51.293 91.821 60.515
201006 345.511 91.962 407.006
201009 336.611 92.162 395.662
201012 325.923 92.474 381.805
201103 317.156 94.283 364.406
201106 307.332 95.235 349.591
201109 298.983 95.727 338.344
201112 171.174 95.213 194.754
201203 156.645 96.783 175.333
201206 147.442 96.819 164.970
201209 140.417 97.633 155.801
201212 123.061 96.871 137.617
201303 108.933 98.209 120.158
201306 110.665 98.518 121.686
201309 95.786 98.790 105.035
201312 72.900 98.326 80.317
201403 53.851 99.695 58.515
201406 108.938 100.560 117.355
201409 96.784 100.428 104.399
201412 83.362 99.070 91.154
201503 60.392 99.621 65.671
201506 129.078 100.684 138.880
201509 118.408 100.392 127.770
201512 113.683 99.792 123.408
201603 102.478 100.470 110.494
201606 113.310 101.688 120.710
201609 98.354 101.861 104.600
201612 64.896 101.863 69.016
201703 47.734 102.862 50.271
201706 34.923 103.349 36.606
201709 32.546 104.136 33.857
201712 18.853 104.011 19.636
201803 12.557 105.290 12.920
201806 12.316 106.317 12.549
201809 11.439 106.507 11.635
201812 9.892 105.998 10.110
201903 8.854 107.251 8.943
201906 -1.593 108.070 -1.597
201909 -1.905 108.329 -1.905

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Adynxx  (OTCPK:ADYX) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Adynxx Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Adynxx's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Adynxx (Adynxx) Business Description

Industry
Traded in Other Exchanges
N/A
Address
100 Pine Street, Suite 500, San Francisco, CA, USA, 94111
Adynxx Inc is a United States-based clinical-stage biopharmaceutical company. It is focused on the development of a new class of therapeutics called transcription factor decoys and bringing to the market novel, disease-modifying products to address unmet needs in the treatment of pain and inflammation. Its pipeline includes brivoligide, a Phase 2 drug candidate intended to address postoperative pain, and AYX2, a pre-clinical candidate intended to treat chronic syndromes of pain, including both inflammatory and neuropathic pain.
Executives
Gregory J. Flesher director 19900 MACARTHUR BLVD., SUITE 550, IRVINE CA 92612
Brian H Dovey 10 percent owner ONE PALMER SQUARE, PRINCETON NJ 08542
Donald C. Manning officer: CHIEF MEDICAL OFFICER C/O PACIRA BIOSCIENCES, INC., 5 SYLVAN WAY, SUITE 300, PARSIPPANY NJ 07054
Pierre Legault director P.O. BOX 1028, C/O STONE MANAGEMENT LLC, BERWYNE PA 19312
Domain Partners Viii, L.p. 10 percent owner C/O DOMAIN ASSOCIATES, L.L.C., ONE PALMER SQUARE, SUITE 515, PRINCETON NJ 08542
Dp Viii Associates, L.p. 10 percent owner C/O DOMAIN ASSOCIATES, L.L.C., ONE PALMER SQUARE, SUITE 515, PRINCETON NJ 08542
Eckard Weber director C/O DOMAIN ASSOCIATES, ONE PALO SQ, PRINCETON NJ 08542
Brian K Halak 10 percent owner C/O DOMAIN ASSOCIATES, ONE PALMER SQUARE, PRINCETON NJ 08542
Nicole Vitullo 10 percent owner 3030 SCIENCE PARK ROAD, SAN DIEGO CA 92121
James C Blair 10 percent owner 5880 PACIFIC CENTER BLVD, SAN DIEGO CA 92121-4204
Jesse I Treu 10 percent owner
Dennis Podlesak director C/O PENINSULA PHARMACEUTICALS, INC., 1751 HARBOR BAY PARKWAY, ALAMEDA CA 94502
Tpg Group Holdings (sbs) Advisors, Inc. 10 percent owner C/O TPG GLOBAL, LLC, 301 COMMERCE STREET, SUITE 3300, FORT WORTH TX 76102
James G Coulter 10 percent owner 301 COMMERCE STREET, SUITE 3300, FORT WORTH TX 76102
David Bonderman 10 percent owner 301 COMMERCE STREET, SUITE 3300, FORT WORTH TX 76102